The pharmacokinetic parameters of theophylline in rats did not change significantly when the drug was intravenously administered after three consecutive days of pretreatment with 17 mg/kg, orally, of 1-furan-2-yl-3-pyridine-2-yl-propenone (FPP-3), an investigatory drug having dual inhibitory action on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). However, significant changes were found in the pharmacokinetic parameters of the drug at doses of 34 mg/kg and more of FPP-3. Results of cytochrome P450 activity test indicated that the alteration in pharmacokinetic parameters of the drug appears to be due to the inhibitory effect of FPP-3 on cytochrome P450 1A which is responsible for the metabolism of theophylline. Methoxyresorufin-O-demethylase (MROD) and ethoxyresorufin-O-deethylase (EROD) activity assays revealed that the relative activities of cytochrome P450 1A1 and 1A2 were dose-dependently reduced in the presence of 1, 5, and 10 μM FPP-3 concentrations. Taking into consideration that FPP-3 is intended to be primarily used by geriatric patients with chronic diseases and therefore may be used in long-term basis, the investigatory drug needs to be assessed thoroughly in terms of drug interaction with other commonly prescribed medications.
在连续三天口服 17 毫克/千克的 1-
呋喃-2-基-3-
吡啶-2-基-
丙烯酮(FPP-3)(一种对环氧合酶(COX)和 5-脂氧合酶(5-LOX)具有双重抑制作用的研究药物)进行预处理后,大鼠体内茶碱的药代动力学参数没有发生显著变化。然而,当 FPP-3 的剂量达到或超过 34 毫克/千克时,药物的药代动力学参数会发生明显变化。细胞色素 P450 活性测试结果表明,药物药代动力学参数的变化似乎是由于 FPP-3 对细胞色素 P450 1A 的抑制作用所致,而细胞色素 P450 1A 负责茶碱的代谢。甲氧基
瑞香素-O-脱甲基酶(MROD)和乙氧基
瑞香素-O-脱乙基酶(EROD)活性测定显示,细胞色素 P450 1A1 和 1A2 的相对活性在 1、5 和 10 μ<小>M小>浓度的 FPP-3 存在下呈剂量依赖性降低。考虑到 FPP-3 主要用于患有慢性疾病的老年患者,因此可能会长期使用,因此需要全面评估该研究药物与其他常用处方药的药物相互作用。